Literature DB >> 31892601

Comparison of Dose Distributions When Using Carbon Ion Radiotherapy Versus Intensity-modulated Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Retrospective Analysis.

Shintaro Shiba1,2, Kei Shibuya3, Motohiro Kawashima2, Naoko Okano3, Takuya Kaminuma3, Masahiko Okamoto3, Yoshiki Kubota2, Takashi Nakano3, Tatsuya Ohno2.   

Abstract

BACKGROUND/AIM: This study compared the dose distributions of carbon ion radiotherapy (C-ion RT) and intensity-modulated radiotherapy (IMRT) in patients with locally advanced hepatocellular carcinoma (LAHCC). PATIENTS AND METHODS: A retrospective analysis was conducted in 10 consecutive patients with LAHCC who had undergone C-ion RT. The dose-volume histogram parameters of clinical plans using C-ion RT at 60 Gy and simulated plans using IMRT at 60 Gy and 50 Gy were compared. We measured the percentage of the normal liver volume that received at least 5 Gy (V5), 10 Gy (V10), 20 Gy (V20), 30 Gy (V30), 40 Gy (V40), and 50 Gy (V50).
RESULTS: The V5, V10, V20, and the mean liver dose were significantly lower in patients who received 60 Gy of C-ion RT than in those who received 50 or 60 Gy of IMRT.
CONCLUSION: C-ion RT exhibits a better liver dose distribution than IMRT in patients with LAHCC. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Carbon ion radiotherapy; hepatocellular carcinoma; intensity-modulated radiotherapy; vascular invasion

Mesh:

Year:  2020        PMID: 31892601     DOI: 10.21873/anticanres.13974

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.

Authors:  Sadahisa Ogasawara; Keisuke Koroki; Hirokazu Makishima; Masaru Wakatsuki; Asahi Takahashi; Sae Yumita; Miyuki Nakagawa; Takamasa Ishino; Keita Ogawa; Kisako Fujiwara; Terunao Iwanaga; Takafumi Sakuma; Naoto Fujita; Ryuta Kojima; Hiroaki Kanzaki; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Ryo Nakagawa; Shingo Nakamoto; Ryosuke Muroyama; Tetsuhiro Chiba; Yoshihito Ozawa; Yohei Kawasaki; Tomoya Kurokawa; Hideki Hanaoka; Hiroshi Tsuji; Naoya Kato
Journal:  BMJ Open       Date:  2022-04-08       Impact factor: 2.692

2.  Long-term survivor of hepatocellular carcinoma treated with repeated carbon ion radiotherapy and transarterial chemoembolization: a case report.

Authors:  Takeru Ohtaka; Shintaro Shiba; Kei Shibuya; Shohei Okazaki; Yuhei Miyasaka; Kento Tomizawa; Masahiko Okamoto; Tatsuya Ohno
Journal:  Clin J Gastroenterol       Date:  2022-06-09

3.  Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.

Authors:  Shintaro Shiba; Kei Shibuya; Masahiko Okamoto; Shohei Okazaki; Shuichiro Komatsu; Yoshiki Kubota; Takashi Nakano; Tatsuya Ohno
Journal:  Radiat Oncol       Date:  2020-08-14       Impact factor: 3.481

4.  Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis.

Authors:  Zheng Li; Qiang Li; Xiaohu Wang; Sha Li; Weiqiang Chen; Xiaodong Jin; Xinguo Liu; Zhongying Dai; Xiongxiong Liu; Xiaogang Zheng; Ping Li; Hui Zhang; Qiuning Zhang; Hongtao Luo; Ruifeng Liu
Journal:  Front Public Health       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.